Data from past clinical trials has provided researchers with a good starting point to create more ECAs.
DCTs proving to solve numerous pain points for patients in clinical research.
The use of virtual trials will surge in the future and could become the de facto standard for clinical studies, says a recent Pistoia Alliance poll.
Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
How pharma companies can reduce the risk of failure with AI-based innovations.
How smart packaging can aid clinical trial adherence.
This paper analyses the responses from more than 800 US-based clinical trial sites to understand their decentralized clinical trial capabilities and perceptions
Sites not expected to fade away even as DCTs continue to grow past COVID-19.
To overcome sponsor-related challenges and work to successfully secure more trials, there are tactical steps CROs can take.
***Live: December 9, 2020, at 11am EST| 8am PST| 4pm GMT| 5pm CET*** In this ‘D-Clinical Age’, leveraging modern technologies and new approaches and mind sets is required to accelerate the development of new treatments. This webinar will examine how data management can drive digital transformation with the right mix of technology, skills and process redesign.***On demand available after airing until Dec. 9, 2021.***
Examining how to optimizing the time and effort of Ethics Committees to efficiently and effectively fulfill their human subjects protection remit.
A look at one company’s platform approach in enabling the engineering of T-cells to identify and destroy cancer.
Datopotamab deruxtecan, the first TROP2-directed DXd antibody drug conjugate, is being evaluated for locally advanced or metastatic nonsquamous non-small cell lung cancer.
For effective rollout on a global scale, sponsors must address and develop a plan around known challenges including recruitment, sit adoption, and technology integration.
Clinical operations professionals, burdened by lack of data standardization, turn to technology in hopes of streamlining regulatory processes for the future.
This piece offers a practical assessment of leveraging various decentralized methodologies and technologies.
Sites not expected to fade away even as DCTs continue to grow past COVID-19.
While Case Report Forms are a main contributor to collected data, non-CRF data such as core laboratory data and central imaging can be critical to any clinical study.
Complicated process of consenting ICU patients can be simplified with a well-designed eConsent platform.
To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.
Virtual trials tools are usually selected early in the protocol development stage, however, due to the COVID-19 crisis, regulators are encouraging sponsors to consider integrating virtual elements into clinical trials already in progress.
Building authentic trust lays at the heart of creating more patient-centric trials.
Statistical methods used via this technique in centralized monitoring.
An overview of patient perceptions of cancer clinical trials and the consent process among those who are currently enrolled in, or who recently completed, a cancer clinical trial.